NYSEHealth CareMedical DevicesSnapshot 2026-07-31
Reading ABT? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Health Care Equipment: fringe margins under pressure (3q confirmed)
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — Adjusted EPS growth to about $5.48 per share in 2026: EPS guidance mid $5.52 vs target $5.48.
View ThesisRevenue is growing steadily — about 7% over the past year.
View GrowthManagement screens strong on capital allocation, earnings delivery, margins, market reaction to earnings.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskAbbott Laboratories needs to maintain strong organic sales growth to justify its price. Revenue grew 13% year over year, and the last quarter beat expectations. It trades at 20× P/E versus a peer median of 33×. The price reflects less growth than forecasted, indicating modest expectations. If Abbott cuts guidance, it could negatively impact the stock. Peer multiples imply a price about 4% below where it trades.
Trailing returns as of 2026-07-31. ABT is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 28 analysts currently covering ABT (as of Jul 2026).
Based on 9 Wall Street analysts offering 12-month price targets for ABT in the last 4 months.
A consensus fair price across 12 valuation methods, at three horizons. As of 2026-08-01. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Health Care Equipment — fair value, gap to price, and forward P/E.
Advances: Expand new product pipeline and regulatory approvals
New product enhances pipeline and regulatory approvals.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-07-31. EPS is implied from price ÷ P/E. Not investment advice.
Current $105.70
The last 12 months of price, then the range of analyst 12-month targets from today’s $105.70.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Top 25% on quality vs scored peers
A second lens on the 12-month fair value: for companies that score high on measured quality (profitability, balance-sheet safety, earnings stability), this read trusts more of today's profit margins instead of averaging them toward their multi-year history the way the headline number does. Shown alongside the fair value above, not in place of it. A diagnostic, not a price target or a buy/sell signal.
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Advances: Achieve adjusted diluted EPS growth with 2026 guidance of $5.45 to $5.60
Raised profit forecast supports EPS growth guidance.
Threatens: Achieve adjusted diluted EPS growth with 2026 guidance of $5.45 to $5.60
Guidance concerns may hinder EPS growth trajectory.
Advances: Achieve EPS growth despite acquisition impact
Increased EPS outlook supports capital allocation objective.
Advances: Drive organic sales growth
Double beat indicates strong organic sales growth.
Legal inquiry could impact reputation and sales growth.
Ending legal probe reduces risk and supports growth objectives.
Lawsuit could impact brand reputation and sales growth.
